Loading interface...

Miglit 50 mg Tablet

Manufactured byBiocon Ltd.
ContainsMiglitol
Description

Miglit 50 mg Tablet is an antidiabetic medicine, which is used to control blood glucose levels. It is used only in patients diagnosed with Type II diabetes mellitus. It may be used in combination with other antidiabetic medicines. Patients are advised to follow a strict diet and exercise regimens along with this medicine to get the best possible effect. This medicine is not recommended for use in children.

Side effects

Major & minor side effects for Miglit 50 mg Tablet

  • Confusion
  • Dizziness and lightheadedness
  • Weakness
  • Shakiness or unsteady walking
  • Increased bowel movements
  • Stomach and abdominal pain
  • Excessive air or gas in stomach
  • Rash

Uses of Miglit 50 mg Tablet

What is it prescribed for?

  • Diabetes Type 2
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effect of this medicine can be observed within 1 hour after oral administration.
  • How long do the effects of this medicine last?
    The time until which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of both low as well as high blood sugar levels. If your diabetes is controlled, moderate consumption of alcohol does not affect sugar levels. However, it is advised that you consult your doctor about all the potential risks and benefits of consuming alcohol during treatment with this medicine.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless necessary. Discuss all the risks and benefits with your doctor before taking this medicine.

Allergy

This medicine is not recommended for use in patients with a known history of allergy to miglitol, or any other inactive ingredients present in the formulation.

Diabetic ketoacidosis

This medicine is not recommended for use in patients with a known history of Diabetic ketoacidosis, a life-threatening complication of diabetes mellitus.

Inflammatory bowel disease

This medicine is not recommended for use in patients with a known history of inflammatory bowel disease, due to the increased risk of worsening of the patient's condition.

Intestinal Obstruction

This medicine is not recommended for use in patients with a known history of intestinal Obstruction, due to the increased risk of worsening of the patient's condition.

Chronic intestinal diseases

This medicine is not recommended for use in patients with a known history of chronic intestinal diseases, due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. Discuss all the risks and benefits with your doctor before taking this medicine.
General warnings

Low blood glucose levels

This medicine should be used with caution due to an increased risk of low blood glucose levels. This risk is especially higher in patients on other anti-diabetic medicines. Frequent monitoring of blood glucose levels is necessary during treatment with this medicine. Appropriate dose adjustments may be done based on the clinical condition.

Gastrointestinal disease

This medicine is not recommended for use in patients with any gastrointestinal diseases like inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease. It is advised that you should inform the doctor about all your medical conditions before starting treatment with this medicine.

Kidney diseases

This medicine should be used with caution in patients with a known history of kidney diseases due to the increased risk of worsening of the patient's condition. Close monitoring of kidney function, appropriate dose adjustments, or replacement with a suitable alternative may be required based on the clinical condition.

Use in children

This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.

Missed Dose

Take the missed dose as soon as you remember it. If it is almost time for your next scheduled dose, skip the missed dose. Do not double the dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of both low as well as high blood sugar levels. If your diabetes is controlled, moderate consumption of alcohol does not affect sugar levels. However, it is advised that you consult your doctor about all the potential risks and benefits of consuming alcohol during treatment with this medicine.
Interaction with Medicine

Dexamethasone

Formoterol

Furosemide

Gatifloxacin

Estradiol

Disease interactions

Diabetic Ketoacidosis

This medicine is not recommended for use in patients with diabetic ketoacidosis, due to the increased risk of worsening of the patient's condition. An alternative treatment option should be considered based on the clinical condition of the patient.

Gastro-intestinal disease

This medicine is not recommended for use in patients with inflammatory bowel disease or any chronic intestinal disease. An alternative treatment option should be considered based on clinical condition. It is advised that you should inform the doctor about all your medical conditions before starting treatment with this medicine.
Food interactions
Information not available.
Lab interactions
Information not available.
Take this medicine exactly as prescribed by the doctor. The dose of the medicine is likely to change based on your body's response to therapy. It is advisable to undergo blood sugar tests at regular intervals to safely use this medicine. You should always carry a sugar candy with you to overcome the unexpected lowering of blood sugar levels. The schedule and duration of use should not be changed without consulting the doctor. Ensure that the course of treatment is completed. Report any adverse effects to the doctor on priority.
Miscelleneous

To be taken with food

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine works by lowering the blood sugar levels in diabetic patients.
Legal Status

Approved

Approved

Approved

Unknown

Classification

Category

Alpha-glucosidase inhibitors

Schedule

Schedule H

Miglitol: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2020 [cited 1 June 2020]. Available from:

https://medlineplus.gov/druginfo/meds/a601079.html

Miglitol - DrugBank [Internet]. Drugbank.ca. 2020 [cited 1 June 2020]. Available from:

https://www.drugbank.ca/drugs/DB00491

Glyset® (miglitol) tablets [Internet]. Dailymed.nlm.nih.gov. 2020 [cited 1 June 2020]. Available from:

https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=75711d16-2d27-476e-a312-d5af448a0e25&type=display

Miglitol Tablets [Internet]. Druginformation.com. 2020 [cited 1 June 2020]. Available from:

http://www.druginformation.com/rxdrugs/M/Miglitol%20Tablets.htm

Internet]. Accessdata.fda.gov. 2020 [cited 1 June 2020]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf

[Internet]. Mri.cts-mrp.eu. 2020 [cited 1 June 2020]. Available from:

https://mri.cts-mrp.eu/human/downloads/NL_H_0116_002_FinalPI.pdf

[Internet]. Labeling.pfizer.com. 2020 [cited 1 June 2020]. Available from:

http://labeling.pfizer.com/ShowLabeling.aspx?id=581
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 5 Jun 2020

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.